Key Points
- Marshall Urist, an EVP at Royalty Pharma, sold 20,000 shares on Jan. 30 at $41.09 and has completed a string of insider sales in recent weeks — roughly 223,151 shares sold for about $8.84 million total.
- Royalty Pharma recently raised its quarterly dividend to $0.235 (annualized $0.94), with an ex-dividend date of Feb. 20 and a payout on Mar. 10, implying a ~2.2% yield and a payout ratio of 66.7%.
- Shares are trading near their 52-week high (opened at $42.36), the company has a market cap of about $24.45B, and analysts hold a consensus "Moderate Buy" with an average target of $47.50 amid several recent upgrades.
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Marshall Urist also recently made the following trade(s):
- On Friday, January 23rd, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $40.26, for a total transaction of $805,200.00.
- On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00.
- On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total value of $815,600.00.
- On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total value of $786,400.00.
- On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.38, for a total transaction of $767,600.00.
- On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
- On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
- On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
- On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
- On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total value of $727,855.80.
Royalty Pharma Trading Up 1.6%
RPRX opened at $42.36 on Tuesday. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $42.38. The business's 50 day moving average is $39.59 and its two-hundred day moving average is $37.79. The firm has a market cap of $24.45 billion, a price-to-earnings ratio of 32.09, a price-to-earnings-growth ratio of 1.59 and a beta of 0.42.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $1.11 by $0.06. The company had revenue of $609.29 million for the quarter, compared to analyst estimates of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. On average, research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.
Royalty Pharma Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be paid a dividend of $0.235 per share. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.2%. Royalty Pharma's dividend payout ratio (DPR) is currently 66.67%.
Hedge Funds Weigh In On Royalty Pharma
A number of institutional investors have recently modified their holdings of the company. Private Trust Co. NA grew its position in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 288 shares during the period. Smartleaf Asset Management LLC boosted its stake in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 790 shares during the last quarter. Financial Consulate Inc. acquired a new stake in Royalty Pharma in the 3rd quarter worth about $35,000. Larson Financial Group LLC grew its holdings in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 306 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in shares of Royalty Pharma by 113.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,428 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 760 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.
Analyst Ratings Changes
Several analysts recently commented on RPRX shares. Weiss Ratings reiterated a "hold (c+)" rating on shares of Royalty Pharma in a research note on Thursday, January 22nd. UBS Group raised shares of Royalty Pharma from a "neutral" rating to a "buy" rating and set a $49.00 target price for the company in a report on Friday. Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a research report on Thursday, December 11th. Morgan Stanley decreased their price target on Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating on the stock in a research note on Friday, October 10th. Finally, Wall Street Zen raised Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 17th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $47.50.
View Our Latest Research Report on RPRX
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
